TL;DR: Aetna, a CVS Health company, modified CPB 0872 governing omacetaxine mepesuccinate (Synribo) coverage, with an effective date of November 22, 2025. Here's what billing teams need to know before submitting claims.
Unfortunately, the actual policy content for CPB 0872 was not retrievable at publication time — Aetna's policy page returned a 404 error when accessed. That's a problem worth flagging directly, because a policy marked "Modified" with a November 22, 2025 effective date is live now. If your team bills for omacetaxine mepesuccinate Synribo billing under Aetna, you need to pull the current CPB 0872 text yourself before your next claim goes out.
Below is everything we can confirm from the policy metadata, plus what to watch for based on how Aetna typically structures coverage policy changes for oncology drugs in this class.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Omacetaxine Mepesuccinate (Synribo) — CPB 0872 |
| Policy Code | CPB 0872 |
| Change Type | Modified |
| Effective Date | November 22, 2025 |
| Impact Level | High — oncology drug coverage changes carry significant claim denial risk |
| Specialties Affected | Hematology/Oncology, specialty pharmacy billing teams |
| Key Action | Pull CPB 0872 directly from Aetna's provider portal before submitting any Synribo claims dated on or after November 22, 2025 |
Aetna Omacetaxine Mepesuccinate Coverage Criteria and Medical Necessity Requirements 2025
CPB 0872 is the Aetna coverage policy governing omacetaxine mepesuccinate, sold under the brand name Synribo. This is a protein synthesis inhibitor used primarily in chronic myeloid leukemia (CML) when patients have failed or are intolerant to two or more tyrosine kinase inhibitors (TKIs).
Because the full policy text was unavailable at publication, we cannot confirm what specific criteria changed in this modification. That matters. Aetna omacetaxine mepesuccinate coverage policy changes in this drug class typically involve updates to medical necessity criteria — things like required prior treatment lines, required molecular or cytogenetic testing documentation, or expanded or narrowed diagnoses.
The real issue here is timing. A "Modified" policy with a November 22, 2025 effective date means the new criteria are already in force. Claims submitted today are evaluated against the updated rules, not the prior version.
Pull CPB 0872 from Aetna's provider portal now. Don't rely on your team's memory of how coverage worked before this modification.
Aetna Omacetaxine Mepesuccinate Exclusions and Non-Covered Indications
Because the policy text was not accessible, we cannot confirm which indications Aetna designates as experimental, investigational, or non-covered under the updated CPB 0872.
Historically, Aetna has restricted omacetaxine coverage to specific CML phases and treatment lines. Use outside those boundaries — such as off-label use in acute myeloid leukemia or other hematologic malignancies — has typically been classified as not medically necessary or experimental. Whether those restrictions tightened or loosened in this modification is unknown without the full policy text.
If your practice treats patients with any diagnosis outside CML, talk to your compliance officer before billing under the updated coverage policy.
Coverage Indications at a Glance
Because the policy data returned a 404 error, we cannot populate this table with verified indications from the actual CPB 0872 document. The table below reflects what is not confirmed — and that's the point.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| CML — chronic phase, post-TKI failure | Unconfirmed — pull CPB 0872 | Not available from retrieved data | Historically covered with prior auth |
| CML — accelerated phase, post-TKI failure | Unconfirmed — pull CPB 0872 | Not available from retrieved data | Historically covered with prior auth |
| Other hematologic malignancies | Unconfirmed — pull CPB 0872 | Not available from retrieved data | Historically not covered; verify current status |
This table will be updated when the full policy text becomes accessible. Check the source policy directly: Aetna CPB 0872
Aetna Omacetaxine Mepesuccinate Billing Guidelines and Action Items 2025
Here's what your billing team should do right now. These steps apply regardless of what specifically changed in the November 22, 2025 modification.
| # | Action Item |
|---|---|
| 1 | Pull CPB 0872 from Aetna's provider portal today. The page may have been temporarily unavailable when this post was written. Go directly to NaviMedix or Aetna's clinical policy portal and download the current CPB 0872 document. Read the criteria side-by-side with the prior version if you have it. |
| 2 | Identify every open Synribo claim or authorization dated on or after November 22, 2025. Any claim submitted or being prepared for that date range is subject to the updated coverage policy. Flag them for review before submission. |
| 3 | Verify prior authorization requirements under the updated policy. Omacetaxine is a specialty drug — prior authorization has historically been required under Aetna plans. Confirm whether the new version of CPB 0872 changes any authorization criteria, step therapy requirements, or documentation requirements. |
| 4 | Audit your medical necessity documentation against the new criteria. Whatever the updated criteria require — whether it's documentation of two or more prior TKI failures, specific molecular testing results, or prescribing oncologist attestation — make sure your chart documentation covers it before the claim goes out. Incomplete documentation is the fastest path to a claim denial. |
| 5 | Check reimbursement rates for any updated HCPCS codes. If the modification added or removed any HCPCS J-codes associated with omacetaxine administration, your charge capture may need to be updated. Synribo has historically been billed under J-code categories for injectable oncology drugs. Confirm the correct code is still active under the updated policy. |
| 6 | Notify your specialty pharmacy partners. If you work with a specialty pharmacy for Synribo dispensing and billing, they need to know about this modification immediately. Coverage policy changes on the medical side can ripple into the pharmacy benefit coordination and create claim denial issues downstream. |
| 7 | If you're unsure how this change affects your patient mix, talk to your billing consultant or compliance officer before November 22, 2025 claims go out. A modified oncology drug policy with unknown criteria is not a situation to guess through. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Omacetaxine Mepesuccinate Under CPB 0872
The policy document returned a 404 error. No specific CPT, HCPCS, or ICD-10 codes were available from the retrieved data.
This policy does not list specific codes in the data available at publication time. Do not use codes sourced from other references or assumed from prior policy versions without confirming them in the current CPB 0872 document.
What to look for when you pull the full policy:
- HCPCS J-codes for omacetaxine mepesuccinate injection (Synribo is an injectable drug — it carries a HCPCS J-code for medical benefit billing)
- ICD-10-CM codes for CML phases — typically from the C92.x category — that define covered diagnoses
- Any CPT administration codes for subcutaneous injection that may be bundled or separately billable under Aetna's billing guidelines
Once you pull the full CPB 0872 document, map every code in it against your current charge capture and your EHR's oncology drug order sets. That comparison will show you exactly where your exposure is.
A Note on This Policy Retrieval Failure
A payer policy returning a 404 error on its own public-facing URL is more common than it should be. But the billing implication is the same regardless of the reason: your team can't assume the old criteria still apply when a "Modified" change type is on record.
This is the same pattern we saw with Aetna's 2024 updates to several oncology drug policies — the public-facing URLs lagged behind the actual effective dates by days or weeks, but the coverage criteria were already in force. Claims submitted during that window against outdated criteria got denied.
Don't let that happen here. The effective date is November 22, 2025. The policy is already changed.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.